Yahoo
NYSE - Delayed Quote USD

Ginkgo Bioworks Holdings, Inc. (DNA)

9.85 -1.36 (-12.13%)
At close: November 2 at 4:00:02 PM EST
9.85 -0.00 (-0.02%)
Pre-Market: 5:38:27 AM EST
Trade DNA on Coinbase
DNA Q3 2026 earnings call
November 5, 2026 at 4:30 PM EST
Chart Range Bar
Loading chart for DNA

What's happening with DNA?

12m ago
Powered by Yahoo Scout

Ginkgo Bioworks remains caught between expanding artificial-intelligence and laboratory-automation partnerships and sharply weaker revenue. Available coverage is pre-earnings, with analysts expecting a smaller per-share loss but another steep revenue decline. The latest authoritative data shows DNA down 0.02% in today’s pre-market move against the prior close, before regular trading opened.

Powered by Yahoo Scout
  • Previous Close 11.21
  • Open 11.35
  • Bid --
  • Ask --
  • Day's Range 9.28 - 11.25
  • 52 Week Range 5.37 - 18.22
  • Volume 3,550,151
  • Avg. Volume 2,226,553
  • Market Cap (intraday) 663.302M
  • Beta (5Y Monthly) 1.74
  • PE Ratio (TTM) --
  • EPS (TTM) -5.06
  • Earnings Date Nov 5, 2026
  • Forward Dividend & Yield -- (0.00%)
  • 1y Target Est 8.00
  • Zacks Rating Neutral

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments. The company offers cell engineering research and development solutions, as well as cell engineering tools comprising functional genomics, antibody developability, and small molecule developability, artificial intelligence models, and reconfigurable automation cart systems on its platform for use in the research, development, and commercialization of engineered organisms and derived products. It also provides biomonitoring and bioinformatics support services through Canopy, which generates genomic data from strategically positioned nodes through biomonitoring programs; and Horizon, a digital surveillance, analytics, and insights platform that detects and monitors biothreats. In addition, the company offers genetic medicine R&D, protein engineering, bioprocess development, crop nutrition and protection solutions, and plant trait optimization. The company serves pharmaceutical and biotechnology, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

www.ginkgo.bio

485

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 11/2/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

DNA
18.53%
S&P 500 (^GSPC)
10.17%

1-Year Return

DNA
24.17%
S&P 500 (^GSPC)
10.25%

3-Year Return

DNA
84.01%
S&P 500 (^GSPC)
74.66%

5-Year Return

DNA
98.16%
S&P 500 (^GSPC)
62.86%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue 20.16M
Earnings -46.71M
Profit Margin -231.74%

Q3

FY25

Q4

FY25

Q1

FY26

Q2

FY26

-80M
-60M
-40M
-20M
0
20M
-400.0%
-350.0%
-300.0%
-250.0%

Analyst Insights

View More

Analyst Price Targets

5.00 Low
8.00 Average
9.85 Current
11.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 10/13/2026
Analyst TD Cowen
Rating Action Maintains
Rating Hold
Price Action Raises
Price Target 9 -> 11

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -219.60%

  • Return on Assets (ttm)

    -16.72%

  • Return on Equity (ttm)

    -59.94%

  • Revenue (ttm)

    132.42M

  • Net Income Avi to Common (ttm)

    -309.64M

  • Diluted EPS (ttm)

    -5.06

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    302.16M

  • Total Debt/Equity (mrq)

    96.15%

  • Levered Free Cash Flow (ttm)

    -72.4M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: